Trials / Suspended
SuspendedNCT00827203
A Safety Study to Determine the Maximum Tolerated Dose of Elesclomol Sodium in Patients With Solid Tumors
A Phase 1 Multi-Dose Dose-Escalation Study of Elesclomol Sodium, Administered Once Weekly to Subjects With Solid Tumors
- Status
- Suspended
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Synta Pharmaceuticals Corp. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this study is to determine the safety and tolerability of elesclomol sodium at escalating doses (ultimately identifying the maximum tolerated dose). This study will also characterize the pharmacokinetics of elesclomol and evaluate its anti-tumor activity in advanced solid tumors that are metastatic and unresectable.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Elesclomol Sodium | Chemotherapy agent |
Timeline
- Start date
- 2009-01-01
- Primary completion
- 2011-01-01
- Completion
- 2011-01-01
- First posted
- 2009-01-22
- Last updated
- 2009-03-09
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00827203. Inclusion in this directory is not an endorsement.